Skip to main
ENTX
ENTX logo

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio Ltd is focused on developing innovative orally delivered macromolecule therapeutics aimed at addressing chronic medical conditions, presenting a strong growth potential given the underserved markets it targets. The recent collaboration with OPKO Health enhances Entera's pipeline by providing access to a promising anti-obesity candidate and advantageous funding terms, which are pivotal for advancing its clinical programs. Positive in vivo pharmacokinetic results for oral formulations not only support the efficacy of Entera's technology but also highlight significant near- and medium-term catalysts that could drive future financial performance.

Bears say

Entera Bio Ltd continues to face significant financial challenges, reporting a net loss of $0.08 per share, primarily driven by higher operating expenses than anticipated. The company is projected to maintain a net loss of $0.05 per share moving forward and will likely require additional capital to support the pivotal clinical development of its lead product candidate, EB613. Furthermore, various risks, including potential delays in clinical advancement and unfavorable market conditions, could impede the company's ability to secure necessary partnerships and achieve successful product commercialization.

ENTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, ENTX has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.